A Phase I/II Study of Pixantrone in Patients with an Aggressive Relapsing Remitting (RR) or Secondary Progressive (SP) Multiple Sclerosis (PIXAMS)

Status unknownPhase 1Phase 2Relapsing and progressive2007-003086-40

What it found

No results found

We found no results in the registry or in papers.

What was tested

Treatment tested

  • Pixantrone

    DNA cross-linking agent

What it measured

Main measures

  • 1. Proportion of patients with a lymphopenia ≤ 1000/mm³ at month 3.

Who could take part

Relapsing and progressive

Show the full criteria

Inclusion criteria

Inclusion: 1. patients with aggressive RR or SP MS who failed to respond to approved immunomodulatory drugs (interferons beta, glatiramer acetate) and who cannot or do not wish to receive mitoxantrone or tysabri. Exclusion: 1. previous treatment with immunosuppressants (Mitoxantrone or other anthracyclines, Cyclophosphamide, Methotrexate, Azathioprine, rituximab, alemtuzumab …) in the past year

Exclusion criteria

Not separately supplied in the registry.

As registered. Criteria can change, so ask the trial team or your neurologist.

About this trial

In the sponsor's words

1. To determine if four consecutive administrations of 120 mg/m² each of PIX (equivalent to 12 mg/m² mitoxantrone) will provide an effective immunosuppression as reflected by a lymphopenia ≤ 1000/mm³ after completion of PIX administration.

Loading reviews and guidelines…

Related trials

History

  1. Status changed from Ongoing to Status unknown
  2. Result signal changed from Ongoing to Status unknown
  1. Started

    Nov 2007

Assembled by software from public sources.